{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:59:47Z","timestamp":1781564387073,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00108-024-01825-w","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:26:24Z","timestamp":1736522784000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa","Treatment of severe flares in Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1007","volume":"66","author":[{"given":"Andreas","family":"Stallmach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Stallhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Grunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/gut.4.4.299","volume":"4","author":"FC Edwards","year":"1963","unstructured":"Edwards\u00a0FC, Truelove\u00a0SC (1963) The Course and Prognosis of Ulcerative Colitis. Gut 4:299\u2013315","journal-title":"Gut"},{"key":"1825_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove\u00a0SC, Witts\u00a0LJ (1955) Cortisone in ulcerative colitis; final report on a\u00a0therapeutic trial. Br Med\u00a0J 2:1041\u20131048","journal-title":"Br Med J"},{"key":"1825_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bmj.2.3800.812","volume":"2","author":"TL Hardy","year":"1933","unstructured":"Hardy\u00a0TL, Bulmer\u00a0E (1933) Ulcerative Colitis: A\u00a0Survey of Ninety-Five Cases. Br Med\u00a0J 2:812\u2013815","journal-title":"Br Med J"},{"key":"1825_CR4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1055\/a-2309-6123","volume":"62","author":"A Sturm","year":"2024","unstructured":"Sturm\u00a0A, Atreya\u00a0R, Bettenworth\u00a0D et\u00a0al (2024) Diagnostik und Therapie des Morbus Crohn der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version\u00a04.1). Z\u00a0Gastroenterol 62:1229\u20131318","journal-title":"Z Gastroenterol"},{"key":"1825_CR5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1055\/a-2271-0994","volume":"62","author":"T Kucharzik","year":"2024","unstructured":"Kucharzik\u00a0T, Dignass\u00a0A, Atreya\u00a0R et\u00a0al (2024) Aktualisierte S3-Leitlinie Colitis ulcerosa (Version\u00a06.2). Z\u00a0Gastroenterol 62:769\u2013858","journal-title":"Z Gastroenterol"},{"key":"1825_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres\u00a0J, Bonovas\u00a0S, Doherty\u00a0G et\u00a0al (2020) ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J\u00a0Crohns Colitis 14:4\u201322","journal-title":"J Crohns Colitis"},{"key":"1825_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine\u00a0T, Bonovas\u00a0S, Burisch\u00a0J et\u00a0al (2022) ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J\u00a0Crohns Colitis 16:2\u201317","journal-title":"J Crohns Colitis"},{"key":"1825_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet\u00a0L, Panes\u00a0J, Sandborn\u00a0WJ et\u00a0al (2016) Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol 14:348\u2013354 e17","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR9","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens\u00a0G, Panaccione\u00a0R, Baert\u00a0F et\u00a0al (2022) Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase\u00a03 ADVANCE and MOTIVATE induction trials. Lancet 399:2015\u20132030","journal-title":"Lancet"},{"key":"1825_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire\u00a0S, Schreiber\u00a0S, Sandborn\u00a0WJ, Dubois\u00a0C, Rutgeerts\u00a0P (2010) Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity. Clin Gastroenterol Hepatol 8:357\u2013363","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR11","first-page":"1051","volume":"89","author":"B Limberg","year":"1994","unstructured":"Limberg\u00a0B, Osswald\u00a0B (1994) Diagnosis and differential diagnosis of ulcerative colitis and Crohn\u2019s disease by hydrocolonic sonography. Am J Gastroenterol 89:1051\u20131057","journal-title":"Am J Gastroenterol"},{"key":"1825_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cgh.2022.05.055","volume":"21","author":"T Kucharzik","year":"2023","unstructured":"Kucharzik\u00a0T, Wilkens\u00a0R, D\u2019Agostino\u00a0MA et\u00a0al (2023) Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn\u2019s Disease. Clin Gastroenterol Hepatol 21:153\u2013163 e12","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR13","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1097\/MIB.0000000000000958","volume":"22","author":"L Beswick","year":"2016","unstructured":"Beswick\u00a0L, Ye\u00a0B, van Langenberg\u00a0DR (2016) Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis 22:2966\u20132976","journal-title":"Inflamm Bowel Dis"},{"key":"1825_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","volume":"51","author":"T Shukla","year":"2017","unstructured":"Shukla\u00a0T, Singh\u00a0S, Tandon\u00a0P, McCurdy\u00a0JD (2017) Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Clin Gastroenterol 51:394\u2013401","journal-title":"J Clin Gastroenterol"},{"key":"1825_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.crohns.2013.12.014","volume":"8","author":"JW Kim","year":"2014","unstructured":"Kim\u00a0JW, Boo\u00a0SJ, Ye\u00a0BD et\u00a0al (2014) Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J\u00a0Crohns Colitis 8:693\u2013701","journal-title":"J Crohns Colitis"},{"key":"1825_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1055\/a-2240-1428","volume":"62","author":"CF Manthey","year":"2024","unstructured":"Manthey\u00a0CF, Epple\u00a0HJ, Keller\u00a0KM et\u00a0al (2024) S2k-Leitlinie Gastrointestinale Infektionen der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z\u00a0Gastroenterol 62:1090\u20131149","journal-title":"Z Gastroenterol"},{"key":"1825_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","volume":"153","author":"H Singh","year":"2017","unstructured":"Singh\u00a0H, Nugent\u00a0Z, Yu\u00a0BN, Lix\u00a0LM, Targownik\u00a0LE, Bernstein\u00a0CN (2017) Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology 153:430\u2013438 e2","journal-title":"Gastroenterology"},{"key":"1825_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","volume":"13","author":"B Balram","year":"2019","unstructured":"Balram\u00a0B, Battat\u00a0R, Al-Khoury\u00a0A et\u00a0al (2019) Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Crohns Colitis 13:27\u201338","journal-title":"J Crohns Colitis"},{"key":"1825_CR19","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1185\/03007995.2012.717529","volume":"28","author":"A Deshpande","year":"2012","unstructured":"Deshpande\u00a0A, Pasupuleti\u00a0V, Patel\u00a0P et\u00a0al (2012) Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. Curr Med Res Opin 28:1553\u20131560","journal-title":"Curr Med Res Opin"},{"key":"1825_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ajg.2016.187","volume":"111","author":"R Razik","year":"2016","unstructured":"Razik\u00a0R, Rumman\u00a0A, Bahreini\u00a0Z, McGeer\u00a0A, Nguyen\u00a0GC (2016) Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. Am J Gastroenterol 111:1141\u20131146","journal-title":"Am J Gastroenterol"},{"key":"1825_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3748\/wjg.v25.i4.418","volume":"25","author":"S Kedia","year":"2019","unstructured":"Kedia\u00a0S, Das\u00a0P, Madhusudhan\u00a0KS et\u00a0al (2019) Differentiating Crohn\u2019s disease from intestinal tuberculosis. World J Gastroenterol 25:418\u2013432","journal-title":"World J Gastroenterol"},{"key":"1825_CR22","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands\u00a0BE, Irving\u00a0PM, Hoops\u00a0T et\u00a0al (2022) Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a\u00a0multicentre, randomised, double-blind, parallel-group, phase\u00a03b\u00a0trial. Lancet 399:2200\u20132211","journal-title":"Lancet"},{"key":"1825_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet\u00a0L, Chapman\u00a0JC, Colombel\u00a0JF et\u00a0al (2024) Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease. N\u00a0Engl J Med 391:213\u2013223","journal-title":"N Engl J Med"},{"key":"1825_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio\u00a0B, Gracie\u00a0DJ, Black\u00a0CJ, Ford\u00a0AC (2023) Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut 72:264\u2013274","journal-title":"Gut"},{"key":"1825_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner\u00a0J, Lemaitre\u00a0M, Carrat\u00a0F, Zureik\u00a0M, Carbonnel\u00a0F, Dray-Spira\u00a0R (2018) Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology 155:337\u2013346 e10","journal-title":"Gastroenterology"},{"key":"1825_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","volume":"21","author":"V Solitano","year":"2023","unstructured":"Solitano\u00a0V, Facciorusso\u00a0A, Jess\u00a0T et\u00a0al (2023) Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A\u00a0Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 21:907\u2013921 e2","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR et\u00a0al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N\u00a0Engl J Med 386:316\u2013326","journal-title":"N Engl J Med"},{"key":"1825_CR28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn\u00a0WJ, Vermeire\u00a0S, Peyrin-Biroulet\u00a0L et\u00a0al (2023) Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase\u00a03\u00a0studies. Lancet 401:1159\u20131171","journal-title":"Lancet"},{"key":"1825_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis\u00a0E, Schreiber\u00a0S, Panaccione\u00a0R et\u00a0al (2024) Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA 332:881\u2013897","journal-title":"JAMA"},{"key":"1825_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione\u00a0R, Ghosh\u00a0S, Middleton\u00a0S et\u00a0al (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392\u2013400 e3","journal-title":"Gastroenterology"},{"key":"1825_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","volume":"22","author":"R Atreya","year":"2024","unstructured":"Atreya\u00a0R, Neurath\u00a0MF (2024) Biomarkers for Personalizing IBD Therapy: The Quest Continues. Clin Gastroenterol Hepatol 22:1353\u20131364","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger\u00a0S, Present\u00a0DH, Kornbluth\u00a0A et\u00a0al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N\u00a0Engl J Med 330:1841\u20131845","journal-title":"N Engl J Med"},{"key":"1825_CR33","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G Jarnerot","year":"2005","unstructured":"Jarnerot\u00a0G, Hertervig\u00a0E, Friis-Liby\u00a0I et\u00a0al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a\u00a0randomized, placebo-controlled study. Gastroenterology 128:1805\u20131811","journal-title":"Gastroenterology"},{"key":"1825_CR34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","volume":"4","author":"DN Moskovitz","year":"2006","unstructured":"Moskovitz\u00a0DN, Van Assche\u00a0G, Maenhout\u00a0B et\u00a0al (2006) Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 4:760\u2013765","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR35","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/ibd\/izab328","volume":"28","author":"D Tarabar","year":"2022","unstructured":"Tarabar\u00a0D, El Jurdi\u00a0K, Traboulsi\u00a0C et\u00a0al (2022) A\u00a0Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis 28:1549\u20131554","journal-title":"Inflamm Bowel Dis"},{"key":"1825_CR36","doi-asserted-by":"publisher","first-page":"175628482312185","DOI":"10.1177\/17562848231218555","volume":"17","author":"F Vitali","year":"2024","unstructured":"Vitali\u00a0F, Rath\u00a0T, Klenske\u00a0E et\u00a0al (2024) Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis. Therap Adv Gastroenterol 17:17562848231218555","journal-title":"Therap Adv Gastroenterol"},{"key":"1825_CR37","doi-asserted-by":"crossref","unstructured":"Choy MC, Suen Li Wai CFD, Con D et al (2024) Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 9: 981-996","DOI":"10.1016\/S2468-1253(24)00200-0"},{"key":"1825_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","volume":"67","author":"D Laharie","year":"2018","unstructured":"Laharie\u00a0D, Bourreille\u00a0A, Branche\u00a0J et\u00a0al (2018) Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 67:237\u2013243","journal-title":"Gut"},{"key":"1825_CR39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","volume":"19","author":"JA Berinstein","year":"2021","unstructured":"Berinstein\u00a0JA, Sheehan\u00a0JL, Dias\u00a0M et\u00a0al (2021) Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A\u00a0Retrospective Case-Control Study. Clin Gastroenterol Hepatol 19:2112\u20132120 e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1825_CR40","doi-asserted-by":"crossref","unstructured":"Berinstein JA, Karl T, Patel A et al (2024) Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience. Am J Gastroenterol  2024 Mar 27: doi: 10.14309\/ajg.0000000000002674.","DOI":"10.14309\/ajg.0000000000002674"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01825-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:29:30Z","timestamp":1737725370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01825-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01825-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A. Stallmach: F\u00f6rderung von der Deutschen Forschungsgemeinschaft (DFG), der Th\u00fcringer Aufbaubank, Abbvie, Celltrion, und Takeda sowie Vortragshonorare von Abbvie, Bristol-Myers Squibb, Celltrion, CLS Behring, De Prom, Falk Foundation, Ferring, Janssen, Kompetenznetz Darmerkrankungen, MedUpdate, MSD, Recordati-Pharma, sobi rare strength, Takeda und Tillots Pharma AG. Beraterhonorare von Abbvie, Amgen, Bristol-Myers Squibb, Consal, Galapagos,\nGilead, Janssen, Lilly, MSD, Repha GmbH, Roche, Pfizer, Pharmacosmos GmbH, Takeda Pharma und Tillots Pharma AG.J. Stallhofer: Honorare von AbbVie, Bristol-Myers Squibb, Falk Foundation, Janssen, MSD, Pfizer und Shire.C. Schmidt: Berater- oder Vortragshonorare von Abbvie, Alanta Health Group, Alfasigma, Amgen, Aristo, art tempi communications, Berlin Chemie, Biogen, Bristol-Myers Squibb, CED Service, Celltrion, Eli Lilly, Emcure, Ewopharma, Dr. Falk, Ferring, Galapagos, Hexal, Janssen-Cilag, Johnson  Johnson, med update, Merckle, MSD Sharp  Dohme, Norgine, Novartis, Olympus, Pentax, Pfizer, Sanofi, Shire, Shield Therapeutics und Takeda.R. Atreya: Honorare von AbbVie, Amgen, Astra Zeneca, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellgene, Celltrion Healthcare, Falk Foundation, Ferring, Galapagos, Gilead, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, Lilly, MSD Sharp  Dohme, Roche Pharma, Samsung Bioepsis, Takeda Pharma, Tillotts Pharma, and Viatris; Forschungsf\u00f6rderung von der DFG f\u00fcr TRR241 (IBDome) und SFB1181 (C02).P.C. Grunert: Vortragshonorare von Abbvie, Falk Foundation, Pfizer, Janssen-Cilag und Takeda Pharma; Beraterhonorare von Abbvie, Janssen-Cilag und Takeda Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}